1 Min Read
June 14 (Reuters) - Mabvax Therapeutics Holdings Inc
* Mabvax Therapeutics reports positive phase 1 results for mvt-2163 immunopet imaging agent
* Mabvax therapeutics holdings inc - mvt-2163 immunopet agent administered in combination with mvt-5873 was safe and well tolerated
* Mabvax Therapeutics holdings inc - "anticipate initiating patient dosing of our mvt-1075 radioimmunotherapy trial later this month"
* Mabvax Therapeutics - for mvt-2163, only toxicities were infusion reactions that resolved on day of injection, with some requiring supportive medication
* Mabvax Therapeutics holdings inc - results showed that mvt-5873 cold antibody pre-dose reduces liver suv facilitating detection of liver metastases
* Mabvax Therapeutics holdings inc - in addition, mvt-5873 cold antibody pre-dose does not interfere with uptake of mvt-2163 on cancer lesions Source text for Eikon: Further company coverage: